Psyence Biomedical Ltd Dossier
Qualitative Analysis
Business overview
Psyence Biomedical Ltd. (Nasdaq: PBM) is a clinical-stage biopharmaceutical company specializing in the development of nature-derived (non-synthetic) psychedelic therapeutics, specifically psilocybin and ibogaine-based medicines, to address unmet mental health needs. The company is a pioneer in its field, being the first life sciences biotechnology company focused on botanical psychedelic medicine to list on the Nasdaq Capital Market. Psyence Biomedical's clinical pipeline is primarily anchored by its lead product candidate, PEX010 (also referred to in clinical activities as NPX-5), a capsule containing naturally sourced psilocybin. The company is evaluating this candidate in a Phase IIb clinical study for the treatment of Adjustment Disorder (AjD) in patients diagnosed with incurable cancer within a palliative care context. Additionally, the company is expanding its strategic focus to include Alcohol Use Disorder and ibogaine-based research.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Securing control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure through strategic investments in PsyLabs. This provides Psyence BioMed with access to licensed, owned, and debt-free production operations, source-level ibogaine supply, natural psilocybin supply, and GMP-compliant manufacturing capabilities.
Expected impact: Materially reduces execution risk, strengthens commercialization preparedness, and supports the generation of real-world validation data.
Partnering with Southern Star Research, a premier Australian Contract Research Organization (CRO), to optimize and accelerate the Phase IIb clinical trial of NPX-5 for Adjustment Disorder.
Expected impact: Enables collaboration with a broader national oncology and mental health network in Australia, accelerating patient recruitment and trial timelines.
Implementation of a capital management framework approved by the Board of Directors, which includes the authorization of a share repurchase program to protect shareholder value and preserve capital to fund planned clinical and regulatory milestones.
Expected impact: Aims to address market undervaluation of common shares while maintaining financial stability to execute core clinical programs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Establishes a vertically integrated platform by securing exclusive, royalty-bearing IP licensing for pharmaceutical-grade, EU GMP-certified, nature-derived psilocybin and source-level ibogaine supply for clinical trials and commercialization.
Terms: Initial 11.13% equity stake acquired in late 2024, followed by a USD $500,000 follow-on investment in April 2025. In February 2026, PsyLabs exercised a put option requiring Psyence BioMed to subscribe for up to US$5,000,000 of PsyLabs shares via a share-for-share exchange.
Serves as the lead Contract Research Organization (CRO) managing the Phase IIb clinical trial evaluating NPX-5 for Adjustment Disorder in Australia.
Terms: Service agreement finalized in May 2025; specific financial terms not publicly disclosed.